Our projects always start with a proven roadmap.

From discovery to planning, our R&D process is built on the very same foundational principles that that big Pharma and VC's use.

Case Studies

Are you ready to reach your next funding or research study milestone, too?
 Read our case studies to learn how we've helped our clients do just that.

Animal studies in oncology

Radyus worked with a preclinical stage academic spinout developing novel drugs for oncology. Given the early stage of the company, our client was mostly funded through grants and had a limited budget for R&D. Radyus was able to work creatively with the client to develop protocols and execute several animal studies, enabling the next round of funding.

View Case Study

Immuno-assay development

Venture-backed biotech company with a newly in-licensed portfolio of novel monoclonal antibodies for oncology. They needed to evaluate the mAbs for efficacy in a new in vitro assay to select a smaller cohort of lead antibodies.

View Case Study

Target product profile (TPP)

Biotech company developing orally delivered enzymes for metabolic diseases needed help prioritizing indications and developing a target product profile for their lead asset.

View Case Study

Product development plan (PDP)

A preclinical biotech company developing novel biologics for treatment of pulmonary diseases needed help developing a PDP and an experienced team of drug developers to execute it.

View Case Study

How we do it.

These five components are the backbone:

  • The cleanroom --a perfected and proprietary ecosystem for growing plants with precision, scale, and with minimum variance.
  • The operating system --an intelligent OS where all the elements are optimized and controlled.
  • The data points----a massive set of data points are generated for research validation and IP.
  • The seeds ---a collaborator's idea that holds the promise,  mixed in with the genetic makeup to make each medicine.
  • The team --our expert hydroponic processing technicians ensure precision and optimization.

Why we do it.

We are transforming the status quo so more medicine can be grown, shared, and produced using molecular pharming. If we can help decentralize drug discovery and production globally for healing and human health, can you imagine the benefits?

The steep prices of biologic drugs are alarming to many patients, physicians, and researchers. It's a bitter pill to swallow for the world when two billion people don't have access to medicine.

In every corner of the world, we envision a Zea Lighthouse that provides a center of excellence for growing therapeutics in plants.

Who we do it for.

For universities, researchers, scientists, and corporations, they get a platform that:

  1. Stabilizes plant growth for the first-time ever
  2. Delivers precision through minimal variation in trial replication batches
  3. Unlocks a depth of rich data collection
  4. Helps validate future research and discovery
  5. Unlocks years of research

For big pharma, they gets access to a novel drug discovery platform that:

  1. Enables much lower drug development costs
  2. Increases development speed
  3. Unlocks a vast selection of target biologics

Why we do it.

We are transforming the status quo so more medicine can be grown, shared, and produced using molecular pharming. If we can help decentralize drug discovery and production globally for healing and human health, can you imagine the benefits?

The steep prices of biologic drugs are alarming to many patients, physicians, and researchers. It's a bitter pill to swallow for the world when two billion people don't have access to medicine.

In every corner of the world, we envision a Zea Lighthouse that provides a center of excellence for growing therapeutics in plants.

Product development plan (PDP)

Client:

Academic spinout developing novel biologics for treatment of pulmonary diseases.

Problem:

The company had many preclinical programs in parallel. They needed guidance on how to prioritize them, select lead indication and execute effectively on a limited budget with aggressive timelines.

Solution:

We formed a project-focused team of experienced drug developers, regulatory,CMC/manufacturing advisors, and project managers. The team developed a detailed, custom drug development plan (PDP) to IND. The client engaged us on a monthly retainer basis to then execute on that plan through our network of vendors. We also assisted the company in meeting with the FDA for the pre-IND meeting.

Results:

By engaging Radyus on a monthly retainer basis ensured wholistic product development planning and effective execution of the novel therapeutic modality. The company is now entering IND-enabling studies.

Related Radyus Services:

+ Product development plan (PDP)

+ Monthly FTE retainer model

+ Pre-IND meeting coordination

+ Regulatory and manufacturing advisory

Target product profile (TPP)

Client:

Biotech company developing orally delivered enzymes for metabolic diseases.

Problem:

Company had an asset efficacious in several metabolic diseases. They needed to prioritize and focus their funds, while maximizing the company value. The company was also actively fundraising and needed clear indication prioritization to attract the right investors, while insuring competitive advantages in the market.

Solution:

We took a systematic approach to indication prioritization by developing a target product profile (TPP) for the lead asset. We conducted in-depth interviews with physicians, payors and investigators in the areas of interest to inform our analysis.

The TPP also provided clear use of proceeds for the next clinical stage of development and informed the experimental roadmap to preclinically validate new claims identified in the TPP.

Results:

The TPP helped formulate clear product development strategy, select lead indication and best position the company for fundraising.

Radyus Related Services:

+ Target product profile

+ Indication selection

+ Fundraising strategy

Animal studies in oncology

Client:

Academic spinout developing novel drugs for oncology.

Problem:

Given the early stage of the company, client was mostly funded through grants and had a limited budget for R&D. Their recent grant was awarded for two animal studies, but with the proposed experimental protocols and their own CRO reach-out, the client was getting quotes three times greater than what the grant would cover.

Solution:

Radyus team worked to first modify these two experimental protocols in such a way that the scope of work was reduced, but the critical data to be collected was preserved. We modified the number of animals, the number of test samples and the dosing schedule.  Then, we reached out to our preferred subcontracting labs for quotes. We have over 2,000 specialty labs in our proprietary database and can do a custom RFP for each project. We identified a lab that could execute both studies under the modified protocols.  We also negotiated  a volume-based discount, enabling us to fit the client’s budget.

Result:

Radyus was able to work creatively with the client ona limited budget and execute both animal studies.

Radyus Related Services:

+ Experimental protocol development

+ Budget-conscious planning

+ Vendor reach-out and management

+ Project management

Immuno-assay development

Client:

Venture-backed, preclinical stage immuno-oncology company

Problem:

Company in-licensed a portfolio of novel monoclonal antibodies but had limited knowledge on the signaling pathway modulated by the antibodies and had no internal expertise in designing in vitro assays to select for efficacy. The company needed to evaluate the antibody portfolio for efficacy in a new in vitro assay to select a smaller cohort of lead antibodies.

Solution:

We conducted scientific diligence to investigate the mechanism of action of  novel antibodies and identify best downstream biomarkers. We then developed protocols for in vitro assays to test efficacy and select a smaller cohort of lead antibodies. We also identified vendors and project managed execution of efficacy experiments. Finally, we informed the next round of critical experiments towards selecting the lead clinical candidate.

Result:

Scientifically and strategically driven product development to accelerate lead candidate selection.

Radyus Related Services:

+ Custom immunoassay development

+ Scientific consulting

+ Lead candidate selection